van 't Klooster G - Search Results

1

Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment.

Baert L, van 't Klooster G, Dries W, François M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Van Remoortere P, Kraus G, Wigerinck P, Rosier J. Baert L, et al. Eur J Pharm Biopharm. 2009 Aug;72(3):502-8. doi: 10.1016/j.ejpb.2009.03.006. Epub 2009 Mar 27. Eur J Pharm Biopharm. 2009. PMID: 19328850

2

Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation.

van 't Klooster G, Hoeben E, Borghys H, Looszova A, Bouche MP, van Velsen F, Baert L. van 't Klooster G, et al. Antimicrob Agents Chemother. 2010 May;54(5):2042-50. doi: 10.1128/AAC.01529-09. Epub 2010 Feb 16. Antimicrob Agents Chemother. 2010. PMID: 20160045 Free PMC article.

3

Powder for reconstitution of the anti-HIV-1 drug TMC278 - Formulation development, stability and animal studies.

Van Gyseghem E, Pendela M, Baert L, Rosier J, Van 't Klooster G, De Man H, Bouche MP, Schueller L, Van Remoortere P, Wigerinck P, Adams E, Hoogmartens J, Van den Mooter G. Van Gyseghem E, et al. Eur J Pharm Biopharm. 2008 Nov;70(3):853-60. doi: 10.1016/j.ejpb.2008.06.030. Epub 2008 Jul 9. Eur J Pharm Biopharm. 2008. PMID: 18657611

4

Co-administration of darunavir and a new pharmacokinetic booster: formulation strategies and evaluation in dogs.

Van Gyseghem E, Baert L, Van Remoortere P, van 't Klooster G, Rouan MC, Voorspoels J, de Kock H, Schueller L, Rosier J, Grooten L, Van den Mooter G. Van Gyseghem E, et al. Among authors: van t klooster g. Eur J Pharm Sci. 2010 Oct 9;41(2):193-200. doi: 10.1016/j.ejps.2010.05.017. Epub 2010 Jun 8. Eur J Pharm Sci. 2010. PMID: 20685614

5

Improved bioavailability of darunavir by use of kappa-carrageenan versus microcrystalline cellulose as pelletisation aid.

Thommes M, Baert L, van 't Klooster G, Geldof M, Schueller L, Rosier J, Kleinebudde P. Thommes M, et al. Eur J Pharm Biopharm. 2009 Aug;72(3):614-20. doi: 10.1016/j.ejpb.2009.03.004. Epub 2009 Mar 20. Eur J Pharm Biopharm. 2009. PMID: 19303929 Clinical Trial.

6

Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.

Reesink HW, Fanning GC, Farha KA, Weegink C, Van Vliet A, Van 't Klooster G, Lenz O, Aharchi F, Mariën K, Van Remoortere P, de Kock H, Broeckaert F, Meyvisch P, Van Beirendonck E, Simmen K, Verloes R. Reesink HW, et al. Gastroenterology. 2010 Mar;138(3):913-21. doi: 10.1053/j.gastro.2009.10.033. Epub 2009 Oct 21. Gastroenterology. 2010. PMID: 19852962 Clinical Trial.

7

Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds.

Lewi P, Arnold E, Andries K, Bohets H, Borghys H, Clark A, Daeyaert F, Das K, de Béthune MP, de Jonge M, Heeres J, Koymans L, Leempoels J, Peeters J, Timmerman P, Van den Broeck W, Vanhoutte F, Van't Klooster G, Vinkers M, Volovik Y, Janssen PA. Lewi P, et al. Drugs R D. 2004;5(5):245-57. doi: 10.2165/00126839-200405050-00001. Drugs R D. 2004. PMID: 15357624

8

TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.

Sankatsing SU, Weverling GJ, Peeters M, van't Klooster G, Gruzdev B, Rakhmanova A, Danner SA, Jurriaans S, Prins JM, Lange JM. Sankatsing SU, et al. AIDS. 2003 Dec 5;17(18):2623-7. doi: 10.1097/00002030-200312050-00009. AIDS. 2003. PMID: 14685056 Clinical Trial.

9

Safety, pharmacokinetics and pharmacodynamics of GLPG0974, a potent and selective FFA2 antagonist, in healthy male subjects.

Namour F, Galien R, Van Kaem T, Van der Aa A, Vanhoutte F, Beetens J, Van't Klooster G. Namour F, et al. Among authors: van t klooster g. Br J Clin Pharmacol. 2016 Jul;82(1):139-48. doi: 10.1111/bcp.12900. Epub 2016 May 1. Br J Clin Pharmacol. 2016. PMID: 26852904 Free PMC article. Clinical Trial.

10

Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.

Vanhoutte F, Mazur M, Voloshyn O, Stanislavchuk M, Van der Aa A, Namour F, Galien R, Meuleners L, van 't Klooster G. Vanhoutte F, et al. Among authors: van t klooster g. Arthritis Rheumatol. 2017 Oct;69(10):1949-1959. doi: 10.1002/art.40186. Epub 2017 Aug 31. Arthritis Rheumatol. 2017. PMID: 28622463 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

43 results

Search Page